Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

CAR-T Digest - August 2020

21 Nov 2024: Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

PYX-201 demonstrated a confirmed 50% objective response rate (ORR) in heavily pretreated HNSCC patients, including one complete response, supporting its potential for monotherapy and combination therapy expansion trials in 1Q25
A 26% ORR was observed across six solid tumor types, with dose-dependent responses, highlighting PYX-201’s novel extracellular targeting mechanism and its potential as a first-in-concept ADC
Pyxis Oncology entered a Clinical Trial Collaboration Agreement with Merck to evaluate PYX-201 in combination with Merck’s KEYTRUDA® in patients with HNSCC, HR+/HER2- breast cancer, TNBC, and sarcoma, with dosing expected to start in 1Q25
PYX-201 was well-tolerated in clinical trials, demonstrating a favorable safety profile with a low incidence of dose-limiting adverse events, and exhibited enhanced molecular stability compared to other ADCs
Pyxis plans to initiate expansion studies in multiple tumor types, including HNSCC, ovarian cancer, NSCLC, HR+/HER2- breast cancer, TNBC, and sarcoma, with preliminary data expected in 2025